Clinical trial · Interventional
A Study to Compare the Efficacy and Safety of Intrapleural Doxycycline Versus Iodopovidone for Performing Pleurodesis in Malignant Pleural Effusion
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Malignant pleural effusion (MPE) arises in advanced-stages of malignancies and frequently heralds a poor prognosis.If the underlying malignancy is chemo sensitive (e.g., small-cell carcinoma of lung \& lymphoma), systemic chemotherapy may control the pleural effusion. Instilling of sclerosing agents into the pleural cavity (pleurodesis) is a common method for the management of MPE. According to a recent survey, tetracycline or its derivative (doxycycline) is the preferred agent for performing pleurodesis at many centers. In a previous study from the investigators' center, the investigators have demonstrated equal efficacy of iodopovidone in comparison to talc in inducing pleural symphysis. Also, iodopovidone has been postulated to have anti-neoplastic effects and hence may help in reducing the drain output. Apart from these benefits iodopovidone is easily available and is cost effective. The investigators believe that iodopovidone will have better efficacy than doxycycline in inducing pleurodesis in malignant pleural effusion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Pleural Effusion | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Doxycycline | Other | — | UNRESOLVED |
| Iodopovidine | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Doxycycline
- description
- Intrapleural doxycycline
- interventionNames
- Other: Doxycycline
- type
- ACTIVE_COMPARATOR
- label
- Iodopovidine
- description
- Intrapleural iodopovidine
- interventionNames
- Other: Iodopovidine
Primary outcomes (3)
- measure
- Complete success
- timeFrame
- 30 days
- description
- long-term relief of symptoms related to the effusion, with absence of re-accumulation of fluid on chest radiograph at 30 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * recurrent symptomatic malignant pleural effusion, with subjective improvement of dyspnea following thoracentesis Exclusion Criteria: * history of any allergy to iodine or doxycycline * history of thyroid disorders * failure of lung expansion after insertion of intercostal tube (trapped lung) * presence of air leaks * advanced malignancy with limited predicted life expectancy (\<30 days) * failure to provide informed consent
References
Publications (1)
- DERIVEDDamaraju V, Sehgal IS, Muthu V, Prasad KT, Dhooria S, Aggarwal AN, Agarwal R. Efficacy and safety of doxycycline versus iodopovidone for pleurodesis through an intercostal tube in malignant pleural effusions: a randomized trial. Support Care Cancer. 2023 Jul 10;31(8):454. doi: 10.1007/s00520-023-07932-y. PMID 37428348